Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDuke Capital Regulatory News (DUKE)

Share Price Information for Duke Capital (DUKE)

Share Price is delayed by 15 minutes
Get Live Data
25.75    0.00 (0.00%)
Bid:
25.50
Ask:
26.00
Spread: 0.50 (1.961%)
Market Cap: £129.66m
DUKE Live PriceLast checked at - London Stock Exchange

Intraday Duke Capital Share Chart

Trading and Operational Update

28 Mar 2024 07:00

RNS Number : 6028I
Duke Capital Limited
28 March 2024
 

28 March 2024

Duke Capital Limited

 

("Duke Capital", "Duke" or the "Company")

 

Trading and Operational Update

 

Duke Capital Limited (AIM: DUKE), a leading provider of hybrid capital solutions for SME business owners in Europe and North America, is pleased to provide the following trading update for its third quarter of the financial year ending 31 December 2023 ("Q3 FY24"), and to provide guidance on trading for its fourth quarter ending 31 March 2024 ("Q4 FY24").

 

Q3 FY24 Trading Update

 

· Recurring revenue for Q3 FY24 reached a record of £6.3 million, an increase of 12% over Q3 FY23. Total cash revenue was also £6.3 million.

 

· Q3 FY24 represents over three continuous years of increasing quarterly recurring cash revenue, with total growth of 350% from the £1.8 million in the quarter ending September 2020 to £6.3 million for the last quarter ending December 2023.

 

Q4 FY24 Trading Guidance

 

· Duke forecasts total cash revenue of £10.2 million in Q4 FY24, a record quarter marking the first time Duke has generated more than £10 million in a single quarter. This represents a material 30% increase over the Company's previous record of £7.8 million which was achieved in Q1 FY24.

 

· During the quarter, Duke delivered two material and profitable buyouts, that have returned over £19 million which the Company will use for near-term deployments in new and existing partners.

 

· Duke expects to achieve recurring cash revenue of £5.8 million in Q4 FY24, a small decrease versus the previous quarter. While the recent buyouts have resulted in increased total cash revenue, until this capital is redeployed, there is a temporary impact of reduced recurring cash revenue. 

 

Overview of quarterly revenue growth:

 

 

Recurring Cash Revenue*

Total Cash Revenue**

Q3 FY23

£5.6 million

£5.6 million

Q4 FY23

£5.7 million

£5.8 million

Q1 FY24

£6.0 million

£7.8 million

Q2 FY24

£6.2 million

£6.2 million

Q3 FY24

£6.3 million

£6.3 million

 

* Recurring cash revenue excludes exit premium receipts and cash gains from equity sales

** Total cash revenue is monthly cash distributions from Duke's partners plus cash gains received from the sales of equity assets and exit premiums

 

 

Operational Update

 

· In February, Duke completed a £2.9 million secondary share purchase from existing shareholders in United Glass Group, increasing its equity stake from 30% to 74%, in line with Duke Capital's vision to deepen its engagement with its high performing partners.

· In March, Duke delivered two highly profitable exits from Fabrikat and Fairmed Healthcare, which has significantly bolstered Duke's liquidity which currently stands at approximately £44 million.

· The Company has a strong pipeline of both new and follow-on opportunities for capital partners to deploy additional liquidity.

· During the quarter, Duke also completed its change of name and renewed messaging. The review has focused on ensuring that Duke's unique offering is communicated to business owners and stakeholders in a way which provides greater clarity and improves comparison when evaluating a broad array of financing options.

 

Neil Johnson, CEO of Duke Capital, said:

 

"We are delighted to show a record quarter of total cash revenue following the successful exits of two of our investments. Fabrikat particularly highlighted the value of Duke's capital, having financed an MBO by three executives in 2021, facilitating an exit three years later at a 36% IRR. We look forward to redeploying the capital from these exits into our pipeline of immediate and longer-term opportunities, driving a return in the short-term to delivering record quarterly recurring cash revenues.

 

Following the completion of our name change and corporate re-branding, Duke Capital is looking forward to FY25 with renewed optimism. With a strengthened liquidity position and strong pipeline, we are well-equipped to navigate the challenges and opportunities that lie ahead, while remaining cautious of the economic backdrop."

 

 

***ENDS***

 

For further information, please visit https://dukecapital.com/ or contact:

 

Duke Capital Limited

Neil Johnson / Charles Cannon Brookes / Hugo Evans

 

+44 (0) 1481 231 816

Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)

Stephen Keys / Callum Davidson / Michael Johnson 

+44 (0) 207 220 0500

 

Canaccord Genuity Limited

(Joint Broker)

 

Adam James / Harry Rees

+44 (0) 207 523 8000

SEC Newgate (Financial Communications)

Elisabeth Cowell / Alice Cho / Matthew Elliott

+ +44 (0) 20 3757 6882 dukecapital@secnewgate.co.uk

 

 

About Duke Capital

 

Duke is a leading provider of hybrid capital solutions for SME business owners in Europe and North America, combining the best features of both equity and debt.

 

Since 2017, Duke has provided unique long-term financing which eliminates re-financing risk and necessity for a short-term exit by providing a unique 'corporate mortgage' while also aligning its returns to grow with the success of the business.

 

Duke is focused on generating attractive risk-adjusted returns for shareholders and has a track record of achieving this across market cycles. It's three investment pillars are capital preservation, attractive dividend yield, and to provide upside upon exits.

 

Duke is listed on the AIM market under the ticker DUKE and is headquartered in Guernsey.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTQKOBPKBKBANB
Date   Source Headline
28th May 20267:00 amRNSNotice of Results & Investor Presentation
31st Mar 20267:00 amRNSTrading and Operational Update
19th Mar 20267:00 amRNSInterim Dividend and Dividend Declaration
26th Jan 20267:00 amRNSDirector/PDMR Shareholding
22nd Dec 20257:00 amRNSFollow-On Investment into Tristone Healthcare Ltd
22nd Dec 20257:00 amRNSFollow-On Investment into Tristone Healthcare Ltd
18th Dec 20257:00 amRNSInterim Dividend and Dividend Declaration
4th Dec 20257:00 amRNSInterim Financial Results
17th Oct 20257:00 amRNSFollow-On Investment into Step Investments Limited
1st Oct 20257:00 amRNSFollow-On Investment into Integrum Group Holdings
29th Sep 20257:00 amRNSTrading Update
18th Sep 20257:00 amRNSInterim Dividend and Dividend Declaration
4th Aug 202511:17 amRNSResult of Annual General Meeting
1st Aug 20258:08 amRNSDirector/PDMR Dealings
11th Jul 20257:00 amRNSAnnual Report & Notice of Annual General Meeting
25th Jun 20257:00 amRNSFinal Results for the year ended 31 March 2025
19th Jun 20257:00 amRNSInterim Dividend and Dividend Declaration
2nd Jun 20257:00 amRNSFollow-On Investment into Existing Capital Partner
27th May 20257:00 amRNSNotice of Results & Investor Presentation
2nd Apr 20257:00 amRNSFollow-On Investment into Existing Capital Partner
31st Mar 20257:00 amRNSTrading and Operational Update
20th Mar 20257:00 amRNSInterim Dividend and Dividend Declaration
19th Feb 20257:00 amRNSFollow-On Investment into BPVA (Ireland) Limited
30th Dec 20247:00 amRNSTrading and Operational Update
17th Dec 202412:50 pmRNSInterim Dividend and Dividend Declaration
16th Dec 20247:00 amRNSInterim Results for the six months ended 30 Sep 24
4th Dec 20249:40 amRNSDirector/PDMR Shareholding
3rd Dec 202411:34 amRNSResult of General Meeting and Issue of Equity
22nd Nov 20243:38 pmRNSResult of Retail Offer and Broker Option
15th Nov 20247:00 amRNSResult of Placing
14th Nov 20245:02 pmRNSRetail Offer to raise up to £3.0 million
14th Nov 20245:01 pmRNSIssue of Equity
30th Sep 20247:00 amRNSTrading and Operational Update
19th Sep 20247:00 amRNSInterim Dividend and Dividend Declaration
3rd Sep 20247:00 amRNSFollow-On Investment into United Glass Group
1st Aug 20243:16 pmRNSDirector/PDMR Dealings
1st Aug 202411:40 amRNSResult of Annual General Meeting
22nd Jul 20247:00 amRNSFollow-On Investment into Step Investments Limited
15th Jul 20247:00 amRNSAnnual Report & Notice of Annual General Meeting
27th Jun 20247:00 amRNSFinal Results for the year ended 31 March 2024
20th Jun 202411:50 amRNSInterim Dividend and Dividend Declaration
3rd Jun 20247:00 amRNSNotice of Results
17th May 202411:45 amEQSHardman & Co Q&A on Duke Capital (DUKE) | Generating investor returns by uniquely meeting customer needs
3rd May 20247:00 amRNSFollow-On Investment into Existing Capital Partner
29th Apr 20242:45 pmEQSHardman & Co Research Initiation of Coverage on Duke Capital (DUKE): Meeting customer needs, giving investors returns
3rd Apr 20247:00 amRNSFollow-On Investment into Existing Capital Partner
2nd Apr 20247:00 amRNSNew Capital Partner - Integrum Care
28th Mar 20247:00 amRNSTrading and Operational Update
21st Mar 20247:00 amRNSInterim Dividend and Dividend Declaration
7th Mar 20247:00 amRNSSuccessful Exit of Investment in Fabrikat

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.